Minorow 5%

Details

Type

Medicines & Treatments

Condition

New

Category

Healthcare,Essentials & Grocery

Ad reference no.

20904

Posted on

06 Sep 2025 12:52 AM

Description

Minorow 5%" is a hair regrowth treatment containing the active ingredient minoxidil, which promotes hair growth and helps prevent further hair loss on the scalp. It is available in Sri Lanka. Hair loss Minoxidil, when applied topically, is used for the treatment of hair loss.it is effective in helping promote hair growth in people with androgenic alopecia regardless of sex.Minoxidil must be used indefinitely for continued support of existing hair follicles and the maintenance of any experienced hair regrowth. Low-dose oral minoxidil (LDOM) is used off-label against hair loss and to promote hair regrowth.Oral minoxidil is an effective and well-tolerated treatment alternative for patients having difficulty with topical formulations. Initial application Minoxidil was developed in the late 1950s by the Upjohn Company (later became part of Pfizer) to treat ulcers. In trials using dogs, the compound did not cure ulcers but proved to be a powerful vasodilator. Upjohn synthesized over 200 variations of the compound, including the one it developed in 1963 and named minoxidil.These studies resulted in the U.S. Food and Drug Administration (FDA) approving minoxidil (with the brand name Loniten) in the form of oral tablets to treat high blood pressure in 1979. Hair growth When Upjohn received permission from the U.S. Food and Drug Administration (FDA) to test the new drug as medicine for hypertension they approached Charles A. Chidsey, at the University of Colorado School of Medicine. He conducted two studies,the second study showing unexpected hair growth. Puzzled by this side-effect, Chidsey consulted Guinter Kahn (who while a dermatology resident at the University of Miami had been the first to observe and report hair development on patients using the minoxidil patch) and discussed the possibility of using minoxidil for treating hair loss.[citation needed] Kahn, along with his colleague Paul J. Grant, had obtained a certain amount of minoxidil and conducted their own research, since they were first to make the side effect observation. Neither Upjohn or Chidsey at the time were aware of the side effect of hair growth.The two doctors had been experimenting with a 1% solution of minoxidil mixed with several alcohol-based liquids.Both parties filed patents to use minoxidil for hair loss prevention, which resulted in a decade-long trial between Kahn and Upjohn, which ended with Kahn's name included in a consolidated patent (U.S. Charles A Chidsey, III and Guinter Kahn) in 1986 and royalties from the company to both Kahn and Grant. Meanwhile, the effect of minoxidil on hair loss prevention was so clear that in the 1980s physicians were prescribing Loniten off-label to their balding patients. In August 1988, the FDA approved minoxidil for treating baldness in men under the brand name "Rogaine" (FDA rejected Upjohn's first choice, Regain, as misleading). The agency concluded that although "the product will not work for everyone", 39% of the men studied had "moderate to dense hair growth on the crown of the head".Men's Rogaine", marketed by Johnson & Johnson went off-patent on January 20, 2006. In 1991, Upjohn made the product available for women.Women's Rogaine", marketed by Johnson & Johnson, went off-patent in February 2014. Pericardial effusion Minoxidil has been implicated in causing pericardial effusions including life-threatening cases of cardiac tamponade.there have been case reports dating back to the 1980s describing this phenomenon, including topical and oral formulations.The frequency of these occurrences has previously been reported at 3% but the true frequency is difficult to determine as a large proportion of patients in this cohort also had renal insufficiency and may have had an effusion preceding the use of minoxidil.

Location

Malabe, Colombo